

DESCRIPTION

Species Reactivity	Equine
Specificity	Detects equine IL-5 in direct ELISAs and Western blots.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant equine IL-5 Leu20-Gly134 Accession # O02699
Conjugate	Alexa Fluor 405 Excitation Wavelength: 405 nm Emission Wavelength: 421 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Neutralization	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Interleukin-5 (IL-5) is a 40 kDa, secreted, heparin-binding, disulfide-linked homodimeric glycoprotein that belongs to the α -helical group of cytokines (1-3). IL-5 is primarily produced by CD4⁺ Th2 cells, but other cell types such as eosinophils, endothelial cells, mast cells, visceral (airway) smooth muscle cells, bronchial epithelium, CD16⁺ NK cells and $\gamma\delta$ T cells can also produce IL-5. Equine IL-5 is synthesized as a 134 amino acid (aa) precursor that contains a 19 aa signal sequence and a 115 aa mature segment. There are four α -helices, two potential N-linked glycosylation sites, and two cysteines that form interchain disulfide bonds with a second, antiparallel IL-5 molecule (3, 4). While human and mouse IL-5 have a potential NLS in their sequence, it is unclear if equine IL-5 has such a sequence. Mature horse IL-5 shares 71%, 89%, 88%, 83%, 66% and 63% aa sequence identity with mature human, bovine, feline, canine, mouse and rat IL-5, respectively.

The receptor for IL-5 consists of a 60 kDa ligand-binding subunit (IL-5 R α) and a 120 kDa signal-transducing subunit (β_c). It is suggested that dimeric IL-5 binding to IL-5 R α recruits β_c , which subsequently covalently links with IL-5 R α . This trimeric complex then associates with another trimeric complex to form the physiologic IL-5 receptor (6). Following binding, IL-5 has targeted effects. It promotes the maturation and migration of eosinophils, partially through the effects of eotaxin. It mobilizes eosinophils and CD34⁺ progenitors from marrow. It also enhances Ig release from B cells and contributes to IL-4 production. Finally, it primes basophils for histamine and leukotriene release (1, 2, 7).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.